CXCR2 and neoplasm: A20-28z CXCR2 T-cells demonstrate superior anti-tumor activity in vivo against αvβ6-expressing tumor xenografts and, although the CAR also engages the mouse ortholog of αvβ6, therapy was well tolerated.